Zevra Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $36,220 | $34,125 | $26,063 | $25,881 |
Gross Profit | 34,323 | 32,605 | 24,510 | 13,502 |
EBITDA | 9,200 | 14,976 | 1,466 | 80,566 |
EBIT | 8,832 | 14,614 | 1,074 | 78,915 |
Net Income | 37,890 | 12,165 | -544 | 74,707 |
Net Change In Cash | 36,220 | 34,125 | 26,063 | 25,881 |
Free Cash Flow | 6,107 | 5,547 | 4,155 | -3,814 |
Cash | 95,595 | 62,406 | 54,439 | 47,712 |
Basic Shares | 60,230 | 57,262 | 55,951 | 56,324 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $106,470 | $23,612 | $27,461 | $10,161 |
Gross Profit | 89,988 | 16,195 | 24,516 | 9,939 |
EBITDA | 98,709 | -76,400 | -43,542 | -25,526 |
EBIT | 94,655 | -82,789 | -44,548 | -26,470 |
Net Income | 83,229 | -105,511 | -46,049 | -26,772 |
Net Change In Cash | 106,470 | 23,612 | 27,461 | 10,161 |
Free Cash Flow | -2,433 | -69,665 | -33,831 | -18,810 |
Cash | 62,406 | 33,785 | 43,049 | 65,466 |
Basic Shares | 57,262 | 46,251 | 35,452 | 34,488 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0.16 |
2025-12-31 | $0.19 |
2025-09-30 | -$0.01 |
2025-06-30 | -$0.06 |